⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for respiratory tract disease

Every month we try and update this database with for respiratory tract disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)NCT04222972
RET-fusion Non ...
Lung Neoplasm
Carcinoma, Non-...
Respiratory Tra...
Thoracic Neopla...
Neoplasms by Si...
Neoplasms
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Disea...
Head and Neck N...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
Neoplasms, Germ...
Neoplasms, Nerv...
Pralsetinib
Carboplatin
Cisplatin
Pemetrexed
Pembrolizumab
Gemcitabine
Paclitaxel
Nab-Paclitaxel
18 Years - Hoffmann-La Roche
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCNCT03134872
Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Thoracic Neopla...
Lung Diseases
Respiratory Tra...
Neoplasms by Si...
Neoplasm, Bronc...
Carcinoma, Bron...
SHR-1210
Carboplatin
Pemetrexed
18 Years - 70 YearsJiangsu HengRui Medicine Co., Ltd.
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsNCT03093116
Locally Advance...
Metastatic Soli...
Oral repotrecti...
12 Years - Turning Point Therapeutics, Inc.
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCNCT03085069
Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Lung Disease
Respiratory Tra...
Neoplasm, Bronc...
Carcinoma, Bron...
SHR-1210
18 Years - 80 YearsJiangsu HengRui Medicine Co., Ltd.
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCNCT03134872
Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Thoracic Neopla...
Lung Diseases
Respiratory Tra...
Neoplasms by Si...
Neoplasm, Bronc...
Carcinoma, Bron...
SHR-1210
Carboplatin
Pemetrexed
18 Years - 70 YearsJiangsu HengRui Medicine Co., Ltd.
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCNCT03085069
Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Lung Disease
Respiratory Tra...
Neoplasm, Bronc...
Carcinoma, Bron...
SHR-1210
18 Years - 80 YearsJiangsu HengRui Medicine Co., Ltd.
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCNCT04862780
Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Neoplasms
Neoplasms by Si...
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
Neoplasms, Nerv...
EGFR T790M
EGFR C797S
EGFR L858R
EGFR Gene Mutat...
EGF-R Positive ...
EGFR Exon 19 De...
EGFR Mutation R...
EGFR Activating...
Protein Kinase ...
Antineoplastic ...
Thoracic Neopla...
BLU-945
osimertinib
18 Years - Blueprint Medicines Corporation
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsNCT03093116
Locally Advance...
Metastatic Soli...
Oral repotrecti...
12 Years - Turning Point Therapeutics, Inc.
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsNCT03037385
RET-altered Non...
Medullary Thyro...
RET-altered Pap...
RET-altered Col...
RET-altered Sol...
Lung Neoplasm
Carcinoma, Non-...
Thyroid Disease...
Thyroid Neoplas...
Thyroid Cancer,...
Carcinoma, Neur...
Respiratory Tra...
Thoracic Neopla...
Neoplasms by Si...
Neoplasms
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Endocrine Syste...
Endocrine Gland...
Head and Neck N...
Adenocarcinoma,...
Adenocarcinoma
Carcinoma
Neoplasms, Glan...
Neoplasms by Hi...
Neuroendocrine ...
Neuroectodermal...
Neoplasms, Germ...
Neoplasms, Nerv...
Colonic Neoplas...
Colorectal Neop...
Intestinal Neop...
Gastrointestina...
Digestive Syste...
Digestive Syste...
Gastrointestina...
Colonic Disease...
Intestinal Dise...
pralsetinib (BL...
18 Years - Hoffmann-La Roche
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsNCT05241873
Lung Neoplasm M...
Carcinoma, Non-...
Respiratory Tra...
Neoplasms
Neoplasms by Si...
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
EGFR Exon 20 Mu...
EGFR Exon 20 In...
EGFR Activating...
Antineoplastic ...
Metastatic Lung...
Brain Metastase...
EGFR-mutated NS...
EGFR Atypical M...
BLU-451
Carboplatin
Pemetrexed
18 Years - Blueprint Medicines Corporation
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCNCT03085069
Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Lung Disease
Respiratory Tra...
Neoplasm, Bronc...
Carcinoma, Bron...
SHR-1210
18 Years - 80 YearsJiangsu HengRui Medicine Co., Ltd.
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCNCT04862780
Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Neoplasms
Neoplasms by Si...
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
Neoplasms, Nerv...
EGFR T790M
EGFR C797S
EGFR L858R
EGFR Gene Mutat...
EGF-R Positive ...
EGFR Exon 19 De...
EGFR Mutation R...
EGFR Activating...
Protein Kinase ...
Antineoplastic ...
Thoracic Neopla...
BLU-945
osimertinib
18 Years - Blueprint Medicines Corporation
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: